NasdaqCM - Nasdaq Real Time Price USD

Aethlon Medical, Inc. (AEMD)

Compare
0.3854 -0.0091 (-2.31%)
At close: November 21 at 4:00 PM EST
0.3790 -0.01 (-1.66%)
After hours: November 21 at 6:58 PM EST
Loading Chart for AEMD
DELL
  • Previous Close 0.3945
  • Open 0.3830
  • Bid --
  • Ask --
  • Day's Range 0.3800 - 0.3949
  • 52 Week Range 0.2400 - 2.3500
  • Volume 74,911
  • Avg. Volume 777,087
  • Market Cap (intraday) 5.381M
  • Beta (5Y Monthly) 1.75
  • PE Ratio (TTM) --
  • EPS (TTM) -2.7900
  • Earnings Date Feb 12, 2025 - Feb 17, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 3.85

Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device for cancer and life-threatening viral infections and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.

www.aethlonmedical.com

14

Full Time Employees

March 31

Fiscal Year Ends

Recent News: AEMD

View More

Performance Overview: AEMD

Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AEMD
82.40%
S&P 500
24.72%

1-Year Return

AEMD
77.33%
S&P 500
30.82%

3-Year Return

AEMD
98.54%
S&P 500
26.62%

5-Year Return

AEMD
98.72%
S&P 500
91.37%

Compare To: AEMD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AEMD

View More

Valuation Measures

Annual
As of 11/20/2024
  • Market Cap

    5.44M

  • Enterprise Value

    -616.84k

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.37

  • Price/Book (mrq)

    0.90

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -50.46%

  • Return on Equity (ttm)

    -105.38%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -11.5M

  • Diluted EPS (ttm)

    -2.7900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.07M

  • Total Debt/Equity (mrq)

    9.98%

  • Levered Free Cash Flow (ttm)

    -5.21M

Research Analysis: AEMD

View More

Company Insights: AEMD

Research Reports: AEMD

View More

People Also Watch